Pfizer (PFE) Other Non-Current Liabilities (2009 - 2026)

Pfizer (PFE) has reported Other Non-Current Liabilities for 18 consecutive years, with $14.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 6.09% year-over-year to $14.8 billion in Q2 2026; TTM through Jun 2026 was $14.8 billion, a 6.09% increase from a year earlier, with the FY2025 full-year figure at $14.7 billion, up 4.06% from the prior year.
• Other Non-Current Liabilities was $14.8 billion for Q2 2026 at Pfizer, up from $14.2 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $16.5 billion in Q4 2023 and troughed at $11.3 billion in Q3 2022.
• A 5-year average of $14.0 billion and a median of $14.0 billion in 2024 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities increased 25.49% in 2023 and decreased 14.44% in 2024, its largest moves.
• Over 5 years, Other Non-Current Liabilities stood at $13.2 billion in 2022, then advanced by 25.49% to $16.5 billion in 2023, then fell by 14.44% to $14.2 billion in 2024, then rose by 4.06% to $14.7 billion in 2025, then rose by 0.37% to $14.8 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $14.8 billion (Q2 2026), $14.2 billion (Q1 2026), and $14.7 billion (Q4 2025), per Business Quant data.